Novartis | NOVN - Operating Expenses


Novartis reported $10.2B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Alcon AG USD 2.41B 4M Mar/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Autolus Therapeutics Ltd USD 85.73M 11.02M Mar/2026
Bayer EUR 10.04B 168M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Fresenius EUR 5.23B 9M Jun/2026
Fresenius Medical Care EUR 4.32B 20.7M Jun/2026
Genmab DKK 748M 77M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
J&J USD 17.83B 388M Jun/2026
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.34B 249M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Orion EUR 345M 42.1M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Philips EUR 3.75B 147M Jun/2026
Recordati EUR 493.59M 11.28M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025